Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer

Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode

(2016) Donglai Wang et al.   NATURE

Phosphatase PP2A is requisite for the function of regulatory T cells

(2016) Sokratis A Apostolidis et al.   NATURE IMMUNOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential

(2016) M-H Hung et al.   ONCOGENE

Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia

(2016) Nameeta P. Richard et al.   Oncotarget

The emerging role of FTY720 (Fingolimod) in cancer treatment

(2016) Christopher White et al.   Oncotarget

Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia

(2015) A. Estella-Hermoso de Mendoza et al.   Journal of Biomedical Nanotechnology

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural basis for inhibition of the histone chaperone activity of SET/TAF-Iβ by cytochromec

(2015) Katiuska González-Arzola et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A

(2015) Man-Hsin Hung et al.   Oncotarget

Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer

(2015) Hao Liu et al.   Oncotarget

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

(2015) Raúl Rincón et al.   Oncotarget

Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis

(2015) Xiaoyong Hu et al.   Scientific Reports

The Nuclear Oncogene SET Controls DNA Repair by KAP1 and HP1 Retention to Chromatin

(2015) Alkmini Kalousi et al.   Cell Reports

SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell

(2014) Hao Liu et al.   CELLULAR SIGNALLING

Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer

(2014) I. Cristobal et al.   CLINICAL CANCER RESEARCH

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

(2014) A. Agarwal et al.   CLINICAL CANCER RESEARCH

Proteomics Identified Overexpression of SET Oncogene Product and Possible Therapeutic Utility of Protein Phosphatase 2A in Alveolar Soft Part Sarcoma

(2014) Daisuke Kubota et al.   JOURNAL OF PROTEOME RESEARCH

Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity

(2014) R Pippa et al.   LEUKEMIA

CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation

(2014) Cheng-Yi Wang et al.   LUNG CANCER

Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer

(2014) Amy S. Farrell et al.   MOLECULAR CANCER RESEARCH

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer

(2014) M. Janghorban et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A

(2014) H-C Yu et al.   Cell Death & Disease

Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720

(2014) Shawn Baldacchino et al.   EPMA Journal

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

(2013) J. J. Oaks et al.   BLOOD

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

(2013) Paolo Neviani et al.   JOURNAL OF CLINICAL INVESTIGATION

Protein phosphatase 2A: a target for anticancer therapy

(2013) Danilo Perrotti et al.   LANCET ONCOLOGY

Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib

(2013) Alfredo Tartarone et al.   LUNG CANCER

A novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery

(2013) Yicheng Mao et al.   Nanomedicine-Nanotechnology Biology and Medicine

Histone chaperones in nucleosome assembly and human disease

(2013) Rebecca J Burgess et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Molecularly targeted cancer therapy: some lessons from the past decade

(2013) Min Huang et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma

(2012) Hui-Chuan Yu et al.   BIOCHEMICAL PHARMACOLOGY

Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity

(2012) Kuen-Feng Chen et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Chromatin remodeling in Cancer: A Gateway to regulate gene Transcription

(2012) Sujit S. Nair et al.   Molecular Oncology

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

(2012) Rocco Piazza et al.   NATURE GENETICS

Fingolimod for Multiple Sclerosis

(2012) Daniel Pelletier et al.   NEW ENGLAND JOURNAL OF MEDICINE

SET protein accumulates in HNSCC and contributes to cell survival: Antioxidant defense, Akt phosphorylation and AVOs acidification

(2012) Andréia M. Leopoldino et al.   ORAL ONCOLOGY

Phosphorylation of SET Protein at Ser171 by Protein Kinase D2 Diminishes Its Inhibitory Effect on Protein Phosphatase 2A

(2012) Atsushi Irie et al.   PLoS One

Phenotypic and genetic characterization of adult T-cell acute lymphoblastic leukemia with del(9)(q34);SET-NUP214 rearrangement

(2011) Hyojin Chae et al.   ANNALS OF HEMATOLOGY

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

(2011) D. J. Christensen et al.   BLOOD

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

(2011) I. Cristobal et al.   HAEMATOLOGICA

Apolipoprotein E and Peptide Mimetics Modulate Inflammation by Binding the SET Protein and Activating Protein Phosphatase 2A

(2011) D. J. Christensen et al.   JOURNAL OF IMMUNOLOGY

Accumulation of the SET protein in HEK293T cells and mild oxidative stress: cell survival or death signaling

(2011) Andréia M. Leopoldino et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

(2011) C H Switzer et al.   ONCOGENE

The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells

(2010) R. Trotta et al.   BLOOD

Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers

(2010) K. G. Roberts et al.   CANCER RESEARCH

Dephosphorylation of Carma1 by PP2A negatively regulates T-cell activation

(2010) Andrea C Eitelhuber et al.   EMBO JOURNAL

Metastasis suppressor function of NM23-H1 requires its 3′-5′ exonuclease activity

(2010) Qingbei Zhang et al.   INTERNATIONAL JOURNAL OF CANCER

I2PP2A regulates p53 and Akt correlatively and leads the neurons to abort apoptosis

(2010) Gong-Ping Liu et al.   NEUROBIOLOGY OF AGING

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transcriptional Regulation by P53

(2010) R. Beckerman et al.   Cold Spring Harbor Perspectives in Biology

Identification of distinct SET/TAF-Iβ domains required for core histone binding and quantitative characterisation of the interaction

(2009) Zoe Karetsou et al.   BMC BIOCHEMISTRY

Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma

(2009) Angel Chao et al.   CANCER LETTERS

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

Clinical-Translational Approaches to the Nm23-H1 Metastasis Suppressor

(2008) P. S. Steeg et al.   CLINICAL CANCER RESEARCH

Multiple pathways regulated by the tumor suppressor PP2A in transformation

(2008) Jukka Westermarck et al.   TRENDS IN MOLECULAR MEDICINE

Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival

(2007) Melissa R. Junttila et al.   FASEB JOURNAL